Table 1.
Target and mechanism of action (MOA) of some of the selective and non-selective drugs used in the treatment of acute myeloid leukemia (AML).
| Selective | Target | MOA | Non-Selective | Target | MOA |
|---|---|---|---|---|---|
| Flavopiridol | CDK Inhibitor | Cell-cycle arrest and apoptosis | Daunorubicin | Anthracycline | Cytotoxic |
| CD33-Targeted ADCs |
CD33 Target | Targeted delivery of toxic drug | Idarubicin | Anthracycline | Cytotoxic |
| Eltanexor | XPO1 Inhibitor | XPO1 inhibition | Mitoxantrone | Anthracycline | Topoisomerase inhibitor |
| Venetoclax | BCL-2 Inhibitor | Anti-apoptotic Protein inhibition | Cytarabine (CPX351) |
Pyrimidine analog | DNA polymerase inhibition |
| Sorafenib | FLT3 Inhibitor | FLT3-ITD inhibition | Guadecitabine | Hypomethylation | DNA Methyltransferase inhibition |
Abbreviations: ADC: antibody-drug conjugate; CDK: cyclin dependent kinase; XPO1: exportin-1; BCL-2: B-cell lymphoma 2; FLT3: FMS-like tyrosine kinase 3; ITD: internal tandem duplication; MOA: mechanism of action.